Jounce Therapeutics

Senior Research Associate, Protein Analytics & Analytical Development

Job ID
2021-1245
Category
Research & Development
Job Location
US-MA-Cambridge

Role / Responsibilities

The Protein Analytical group at Jounce Therapeutics is looking for an individual with experience in protein characterization and antibody developability assessment. The successful candidate will play an important role in the discovery and development of novel biotherapeutics for immuno-oncology.  He/she/they will be expected to participate in experimental design, conduct experiments, optimize throughput, maintain detailed records, and generate standard operating procedures.  This is an exciting opportunity to play an important role in the discovery and development of novel biotherapeutics for immuno-oncology.  In this role you will have the opportunity to work cross functionally across multiple departments including discovery/biology, pre-clinical, Ab technology, protein production and CMC. The ideal candidate will have protein biochemistry and antibody discovery knowledge and be proficient at designing and executing lab experiments.

 

Responsibilities

  • Act as key point person in protein characterization/developability assessment teams
  • Monitor and maintain equipment and instruments regularly to ensure proper operation and calibration.
  • Prepare SOPs and reports
  • Independently lead and develop new experiments, technological or scientific processes
  • Proactively share skills/knowledge with others to broaden company capabilities
  • Take a leadership role within the lab
  • 100% laboratory based

Qualifications

  • BS with 2+ years or MS 0 to 3 years industrial experience in protein biochemistry/biophysics fields.
  • Hands-on experience with 2 or more of the following techniques:  H/UPLC, DSC, DLS, SEC-MALS, icIEF, and CE-SDS techniques.
  • Experience with antibody discovery, developability assessment and characterization.
  • Excellent bench skills and strong documentation skills.
  • Strong attention to detail and generating quality data.
  • Team player with good communication skills and ability to work cross functionally

Statement

Jounce Therapeutics is an equal opportunity employer and does not discriminate in its employment decisions on the basis of race, color, national origin, age, physical or mental disability, marital status, religion, creed, sex, or political beliefs.  We offer a competitive salary and benefits package. All applicants should be legally entitled to work for any employer in the U.S.

Company Summary

Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. Jounce’s highest priority program, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown to reprogram immune-suppressive tumor associated macrophages to an anti-tumor state in preclinical studies. A Phase 1 clinical trial, named INNATE, for JTX-8064 as a monotherapy and in combination with JTX-4014, Jounce’s internal PD-1 inhibitor, or pembrolizumab is currently enrolling patients with advanced solid tumors. Jounce’s most advanced product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS, and is currently being studied in the SELECT Phase 2 trial. JTX-4014 is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounce’s broader pipeline. Additionally, Jounce exclusively licensed worldwide rights to JTX-1811, a monoclonal antibody targeting CCR8 and designed to selectively deplete T regulatory cells in the tumor microenvironment, to Gilead Sciences, Inc. For more information, please visit www.jouncetx.com.

Options

Sorry the Share function is not working properly at this moment. Please refresh the page and try again later.
Share on your newsfeed